Phase II dose escalation study of caspofungin for invasive Aspergillosis.

1st Department of Internal Medicine, University Hospital of Cologne, Kerpener Str 62, 50937 Cologne, Germany.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.57). 09/2011; 55(12):5798-803. DOI: 10.1128/AAC.05134-11
Source: PubMed

ABSTRACT Our objective was to evaluate the maximum tolerated dose of caspofungin for invasive aspergillosis (IA). The safety and pharmacokinetics of escalating dosages of caspofungin were investigated in IA. Eight patients each received caspofungin 70, 100, 150, or 200 mg once a day (QD). Dose-limiting toxicity (DLT) was defined as the same non-hematological treatment-related adverse event of grade ≥ 4 in 2 of 8 patients or ≥ 3 in 4 of 8 patients in a cohort. A total of 46 patients (median age, 61 years; 21 female; 89% with hematological malignancies) received caspofungin (9, 8, 9, and 20 patients in the 70-, 100-, 150-, and 200-mg cohorts) for a median of 24.5 days. Plasma pharmacokinetics were linear across the investigated dosages and followed a two-compartment model, with weight as the covariate on clearance and sex as the covariate on central volume of distribution. Simulated peak plasma concentrations at steady state ranged from 14.2 to 40.6 mg/liter (28%), trough concentrations from 4.1 to 11.8 mg/liter (58%), and area under the concentration-time curve from 175 to 500 mg/liter/h (32%) (geometric mean, geometric coefficient of variation). Treatment was well tolerated without dose-limiting toxicity. The rate of complete or partial responses was 54.3%, and the overall mortality at 12-week follow-up was 28.3%. In first-line treatment of invasive aspergillosis, daily doses of up to 200 mg caspofungin were well tolerated and the maximum tolerated dose was not reached. Pharmacokinetics was linear. Response rates were similar to those previously reported for voriconazole and liposomal amphotericin.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal disease (IFD) remains life threatening in premature infants and immunocompromised children despite the recent development of new antifungal agents. Optimal dosing of antifungals is one of the few factors clinicians can control to improve outcomes of IFD. However, dosing in children cannot be extrapolated from adult data because IFD pathophysiology, immune response, and drug disposition differ from adults. We critically examined the literature on pharmacokinetics (PK) and pharmacodynamics (PD) of antifungal agents and highlight recent developments in treating pediatric IFD. To match adult exposure in pediatric patients, dosing adjustment is necessary for almost all antifungals. In young infants, the maturation of renal and metabolic functions occurs rapidly and can significantly influence drug exposure. Fluconazole clearance doubles from birth to 28 days of life and, beyond the neonatal period, agents such as fluconazole, voriconazole, and micafungin require higher dosing than in adults because of faster clearance in children. As a result, dosing recommendations are specific to bracketed ranges of age. PD principles of antifungals mostly rely on in vitro and in vivo models but very few PD studies specifically address IFD in children. The exposure-response relationship may differ in younger children compared with adults, especially in infants with invasive candidiasis who are at higher risk of disseminated disease and meningoencephalitis, and by extension severe neurodevelopmental impairment. Micafungin is the only antifungal agent for which a specific target of exposure was proposed based on a neonatal hematogenous Candida meningoencephalitis animal model. In this review, we found that pediatric data on drug disposition of newer triazoles and echinocandins are lacking, dosing of older antifungals such as fluconazole and amphotericin B products still need optimization in young infants, and that target PK/PD indices need to be clinically validated for almost all antifungals in children. A better understanding of age-specific PK and PD of new antifungals in infants and children will help improve clinical outcomes of IFD by informing dosing and identifying future research areas.
    Drugs. 05/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Killing rates (K) of 1-32 mg ml-1 caspofungin was determined in RPMI-1640 and in 50% serum using time-kill methodology against three C. krusei (MIC of all three isolates 0.25 mg ml-1 in RPMI-1640 and 2 mg ml-1 in serum) and three C. inconspicua clinical isolates (MIC ranges 0.06-0.12 mg ml-1 in RPMI-1640 and 0.25-0.5 mg ml-1 in serum), against C. krusei ATCC 6258 and against one C. krusei isolate resistant to echinocandins (MIC 8 mg ml-1 in RPMI-1640 and 32 mg ml-1 in serum). In RPMI-1640, the highest mean K values were observed at 4 (-1.05 h-1) and 16 (-0.27 h-1) mg ml-1 caspofungin for C. krusei and C. inconspicua clinical isolates, respectively. In 50% serum, mean K value ranges at 1-32 and 4-32 mg ml-1 concentrations for C. inconspicua and C. krusei were -1.12 to -1.44 h-1 and -0.42 to -0.57, respectively. While K values against C. krusei in RPMI-1640 and 50% serum were comparable, serum significantly increased the killing rate against C. inconspicua (P<0.0003 for all tested concentrations). In a neutropenic murine model daily 1, 2, 3, 5 and 15 mg/kg caspofungin significantly decreased the fungal tissue burden of C. inconspicua in the kidneys (P<0.05-0.001). Against C. krusei, doses 3, 5 and 15 mg/kg were effective (P<0.05-0.01). All effective doses were comparably efficacious for both species. Fifteen mg/kg caspofungin was effective even against the echinocandin resistant C. krusei isolate. In 50% serum, killing was concentration independent at effective concentrations (≥4 mg ml-1 and ≥1 mg ml-1 for C. krusei and C. inconspicua, respectively), suggesting that the efficacy of dose escalation is questionable. These in vitro results were also supported by the murine model.
    Journal of Medical Microbiology 11/2013; · 2.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Apparently immunocompetent critically ill patients represent an increasing population at risk for invasive pulmonary aspergillosis (IPA). The current review gives an update on the epidemiology, diagnosis, and management of IPA in the ICU. Patients without apparent severe immunosuppression (e.g. chronic obstructive pulmonary disease, decompensated liver disease, etc.) represent the majority of ICU IPA cases. IPA diagnosis is problematic and the true incidence of IPA is difficult to be estimated because of the nonspecific clinical presentation. A user-friendly clinical diagnostic algorithm for IPA is valuable, particularly through a high negative predictive value. IPA carries a poor prognosis and has an important impact on hospital costs. Timely diagnosis and prompt administration of appropriate treatment may improve the outcomes. Intravenous voriconazole is the recommended primary IPA treatment, but liposomal amphotericin B also has clinical utility. Voriconazole presents bioavailability and toxicity issues, and drug level monitoring is advocated. Caspofungin or antifungal combinations are recommended as salvage therapy. A high level of suspicion in critically ill patients presenting with Aspergillus-positive respiratory tract cultures or nonresolving pulmonary infection may lead to earlier IPA diagnosis. Dosage individualization may decrease treatment discontinuation and improve clinical efficacy.
    Current Opinion in Infectious Diseases 02/2014; · 4.87 Impact Factor

Full-text (2 Sources)

Available from
Jun 1, 2014